Pediatric Endocrine Institute, Ha'Emek Medical Center, Afula, Israel.
Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.
Front Endocrinol (Lausanne). 2020 Jun 5;11:309. doi: 10.3389/fendo.2020.00309. eCollection 2020.
Autoimmune thyroiditis (AIT) is the most common cause of acquired hypothyroidism in children. The natural outcome of AIT in childhood has been reported previously however follow-up duration is generally short and results variable. To characterize clinical and biochemical findings at presentation of AIT, evaluate long-term outcomes and assess which factors at presentation predict evolution over time. 201 children under 18 years of age at presentation (82% female) were enrolled. Subjects were divided into five subgroups according to thyroid stimulating hormone (TSH) level at referral. Mean follow-up was 8.1 years (range 0-29 years). At presentation, 34% of patients had overt hypothyroidism, 32% subclinical hypothyroidism (SCH), 16% compensated hypothyroidism, 14% were euthyroid, and 3.7% had Hashitoxicosis. Children with overt hypothyroidism were younger (10.6 vs. 13.2 years) and had higher thyroid peroxidase antibody titers. At the time of the study, levothyroxine (LT) therapy was required in 26% of children who were euthyroid at presentation, 56% of SCH patients, 83-84% of those with TSH above 10 mIU/L, and 57% of those with Hashitoxicosis. Over the years, 16% of children presenting with overt hypothyroidism stopped therapy. Free T at presentation was the only predictor of outcome over time. Our findings suggest that only 26% children who were euthyroid at presentation developed hypothyroidism, whereas over 50% of those with SCH went on to require treatment. Of those presenting with overt hypothyroidism, 16% recovered with time. The only predictive parameter for LT therapy at the end of the study was free T levels at presentation. Long-term follow-up is required to determine ongoing therapy needs and screen for additional autoimmune diseases.
自身免疫性甲状腺炎(AIT)是儿童获得性甲状腺功能减退症最常见的原因。此前曾报道过儿童 AIT 的自然病程,但随访时间通常较短,结果也各不相同。本研究旨在描述 AIT 患儿就诊时的临床和生化表现,评估长期结局,并评估就诊时的哪些因素可预测随时间的演变。共纳入 201 名年龄在 18 岁以下(82%为女性)的患儿。根据就诊时促甲状腺激素(TSH)水平,将受试者分为 5 个亚组。平均随访时间为 8.1 年(0-29 年)。就诊时,34%的患者为显性甲状腺功能减退症,32%为亚临床甲状腺功能减退症(SCH),16%为代偿性甲状腺功能减退症,14%为甲状腺功能正常,3.7%为桥本甲状腺毒症。显性甲状腺功能减退症患儿更年轻(10.6 岁 vs. 13.2 岁),甲状腺过氧化物酶抗体滴度更高。研究时,26%就诊时甲状腺功能正常的患儿、56% SCH 患者、TSH>10 mIU/L 的患者 83-84%、桥本甲状腺毒症的患者 57%需要接受左甲状腺素(LT)治疗。多年来,16%的显性甲状腺功能减退症患儿停止了治疗。就诊时游离 T 是预测随时间变化结局的唯一指标。本研究结果表明,仅有 26%就诊时甲状腺功能正常的患儿出现甲状腺功能减退症,而超过 50%的 SCH 患者需要治疗。显性甲状腺功能减退症患者中,16%随时间恢复。研究结束时 LT 治疗的唯一预测参数是就诊时游离 T 水平。需要长期随访以确定持续的治疗需求,并筛查其他自身免疫性疾病。